BS_G3RJTBZD
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 17.969776609724047
- age_years
- 7.967
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.466
- OXIDATIVE_PHOSPHORYLATION+0.466
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.417
- UNFOLDED_PROTEIN_RESPONSE+0.415
- FATTY_ACID_METABOLISM+0.409
- ADIPOGENESIS+0.408
- HYPOXIA+0.386
- INTERFERON_ALPHA_RESPONSE+0.381
- MTORC1_SIGNALING+0.346
- CHOLESTEROL_HOMEOSTASIS+0.339
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.442
- APICAL_SURFACE-0.413
- ANGIOGENESIS-0.400
- INFLAMMATORY_RESPONSE-0.340
- KRAS_SIGNALING_UP-0.256
- PANCREAS_BETA_CELLS-0.210
- KRAS_SIGNALING_DN-0.193
- IL6_JAK_STAT3_SIGNALING-0.181
- E2F_TARGETS-0.137
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.136
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A0DA6087-9D43-41F9-8569-9F9320E4A9E8 | — | — | 0.835 |
| 2 | SRR6013510 | — | cohortA4 | 0.800 |
| 3 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.796 |
| 4 | b0363d99-5ff4-42cd-849d-79dfad0eaf49 | — | — | 0.784 |
| 5 | ULC1452T_S57 | — | cohortA1 | 0.783 |
| 6 | EA6A086B-F655-47E8-9E70-8A2D36FC2AE1 | — | — | 0.782 |
| 7 | SRR6013565 | — | cohortA4 | 0.760 |
| 8 | F2FCC449-3487-474C-82A6-8F2ED71E41BC | — | — | 0.760 |
| 9 | SRR6013598 | — | cohortA4 | 0.757 |
| 10 | 656B6084-9C58-469A-BEAF-FFC1D089E658 | — | — | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.466 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.466 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.417 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.415 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.409 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.408 | Inavolisib | — uncovered |
| HYPOXIA | 0.386 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.381 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.346 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.339 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.324 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.299 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.297 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.263 | Temsirolimus | — uncovered |
| PEROXISOME | 0.245 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.203 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.202 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.184 | Inavolisib | — uncovered |